Last reviewed · How we verify
BRCA mutation-positive and HER2-negative breast cancer
Approved treatments
- Lynparza · University of Texas Southwestern Medical Center
- Lynparza · AstraZeneca
Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- BRCA mutation-positive and HER2-negative breast cancer patent landscape — cliff calendar, originator estates, attackable patents
- BRCA mutation-positive and HER2-negative breast cancer treatment landscape brief
- BRCA mutation-positive and HER2-negative breast cancer treatment updates RSS
Frequently asked questions about BRCA mutation-positive and HER2-negative breast cancer
What drugs treat BRCA mutation-positive and HER2-negative breast cancer?
Tracked treatments include Lynparza.
What is the treatment for BRCA mutation-positive and HER2-negative breast cancer?
Standard treatment for BRCA mutation-positive and HER2-negative breast cancer includes Lynparza. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: BRCA mutation-positive and HER2-negative breast cancer patent cliff · BRCA mutation-positive and HER2-negative breast cancer CI report
- Treatment: Lynparza · University of Texas Southwestern Medical Center
- Treatment: Lynparza · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing